Stroke Risk Stratification in a "Real-World" Elderly Anticoagulated Atrial Fibrillation Population

被引:68
作者
Poli, Daniela [1 ]
Lip, Gregory Yh [2 ]
Antonucci, Emilia [1 ]
Grifoni, Elisa [1 ]
Lane, Deirdre [2 ]
机构
[1] Azienda Osped Univ Careggi, Thrombosis Ctr, Dept Heart & Vessels, Florence, Italy
[2] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
关键词
atrial fibrillation; stroke; elderly; anticoagulion; aspirin; PREDICTING STROKE; CHADS(2) SCORE; ANTITHROMBOTIC THERAPIES; THROMBOEMBOLISM; WARFARIN; DEATH;
D O I
10.1111/j.1540-8167.2010.01858.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Methods: Six hundred and sixty-two consecutive AF patients (mean [SD] age 74 [7.7] years; 36.1% female) referred to the Anticoagulation Clinic of the Azienda Ospedaliera Careggi of Florence, Italy, were included and followed-up for a mean 3.6 +/- 2.7 years for the incidence of thromboembolic (TE) events. The ability of the new CHA(2)DS(2)-VASc schema to predict TE was compared with other contemporary stroke risk schema (including CHADS(2), NICE 2006, ACC/AHA/ESC 2006, and ACCP 2008), by determining the c-statistic. Results: Univariate predictors of TE events were female gender (odds ratio 1.9; 95%CI [confidence intervals] 1.01-3.70) and previous stroke/transient ischemic attack (TIA)/TE (OR 5.6; 95%CI 2.70-11.45), although after adjustment only previous stroke/TIA/TE was an independent predictor of TE (OR 5.5; 95%CI 2.68-11.31; P = 0.0001). All stroke risk schema had modest discriminating ability, with c-statistics ranging from 0.54 (atrial fibrillation investigators [AFI]) to 0.72 (CHA(2)DS(2)-VASc). The CHADS(2) and CHA(2)DS(2)-VASc schemes having the best c-statistics (0.717 and 0.724, respectively) with significant discriminating value between risk strata (both P < 0.001). The proportion of patients assigned to individual risk categories varied widely across the schema, with those categorized as "moderate-risk" ranging from 5.3% (CHA(2)DS(2)-VASc) to 49.2% (CHADS(2)-classical). Conclusion: In this "real world" cohort, current published risk schemas have modest predictive ability, with the CHADS(2) and CHA(2)DS(2)-VASc schemes having the best predictive value for thromboembolism. Future trials could assess the value of alternative strategies for thromboprophylaxis in high-risk anticoagulated patients identified by these schemes. (J Cardiovasc Electrophysiol, Vol. 22, pp. 25-30, January 2011).
引用
收藏
页码:25 / 30
页数:6
相关论文
共 23 条
[1]  
[Anonymous], ATR FIBR NAT CLIN GU
[2]   Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? [J].
Baruch, Lawrence ;
Gage, Brian F. ;
Horrow, Jay ;
Juul-Moller, Steen ;
Labovitz, Arthur ;
Persson, Maria ;
Zabalgoitia, Miguel .
STROKE, 2007, 38 (09) :2459-2463
[3]   Warfarin Is Not Needed in Low-Risk Patients Following Atrial Fibrillation Ablation Procedures [J].
Bunch, T. Jared ;
Crandall, Brian G. ;
Weiss, J. Peter ;
May, Heidi T. ;
Bair, Tami L. ;
Osborn, Jeffrey S. ;
Anderson, Jeffrey L. ;
Lappe, Donald L. ;
Muhlestein, J. Brent ;
Nelson, Jennifer ;
Allison, Scott ;
Foley, Thomas ;
Anderson, Lars ;
Day, John D. .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2009, 20 (09) :988-993
[4]   Challenges of establishing new antithrombotic therapies in atrial fibrillation [J].
Connolly, Stuart J. ;
Eikelboom, John ;
O'Donnell, Martin ;
Pogue, Janice ;
Yusuf, Salim .
CIRCULATION, 2007, 116 (04) :449-455
[5]   ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society [J].
Fuster, Valentin ;
Ryden, Lars E. ;
Cannom, David S. ;
Crijns, Harry J. ;
Curtis, Anne B. ;
Ellenbogen, Kenneth A. ;
Halperin, Jonathan L. ;
Le Heuzey, Jean-Yves ;
Kay, G. Neal ;
Lowe, James E. ;
Olsson, S. Bertil ;
Prystowsky, Eric N. ;
Tamargo, Juan Luis ;
Wann, Samuel .
CIRCULATION, 2006, 114 (07) :E257-E354
[6]   Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].
Gage, BF ;
Waterman, AD ;
Shannon, W ;
Boechler, M ;
Rich, MW ;
Radford, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870
[7]   Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1 [J].
Gorin, Laurent ;
Fauchier, Laurent ;
Nonin, Emilie ;
de Labriolle, Axel ;
Haguenoer, Ken ;
Cosnay, Pierre ;
Babuty, Dominique ;
Charbonnier, Bernard .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) :833-840
[8]  
Hart RG, 2007, NEUROLOGY, V69, P546
[9]   Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk - The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) [J].
Healey, Jeff S. ;
Hart, Robert G. ;
Pogue, Janice ;
Pfeffer, Marc A. ;
Hohnloser, Stefan H. ;
De Caterina, Raffaele ;
Flaker, Greg ;
Yusuf, Salim ;
Connolly, Stuart J. .
STROKE, 2008, 39 (05) :1482-1486
[10]   Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data [J].
Hughes, Michael ;
Lip, Gregory Y. H. .
THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) :295-304